BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26271008)

  • 21. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
    Schulz-Heddergott R; Moll UM
    Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29875343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.
    Vogiatzi F; Brandt DT; Schneikert J; Fuchs J; Grikscheit K; Wanzel M; Pavlakis E; Charles JP; Timofeev O; Nist A; Mernberger M; Kantelhardt EJ; Siebolts U; Bartel F; Jacob R; Rath A; Moll R; Grosse R; Stiewe T
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):E8433-E8442. PubMed ID: 27956623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis through MDM2-Mediated Ubiquitination and Destabilization of p53.
    Chen Y; Xin H; Peng H; Shi Q; Li M; Yu J; Tian Y; Han X; Chen X; Zheng Y; Li J; Yang Z; Yang L; Hu J; Huang X; Liu Z; Huang X; Zhou H; Cui X; Li F
    Cancer Res; 2020 Jun; 80(11):2175-2189. PubMed ID: 32066565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246.
    Cooks T; Pateras IS; Jenkins LM; Patel KM; Robles AI; Morris J; Forshew T; Appella E; Gorgoulis VG; Harris CC
    Nat Commun; 2018 Feb; 9(1):771. PubMed ID: 29472616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
    Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
    Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ubiquitination and degradation of mutant p53.
    Lukashchuk N; Vousden KH
    Mol Cell Biol; 2007 Dec; 27(23):8284-95. PubMed ID: 17908790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNAJA1 promotes cancer metastasis through interaction with mutant p53.
    Kaida A; Yamamoto S; Parrales A; Young ED; Ranjan A; Alalem MA; Morita KI; Oikawa Y; Harada H; Ikeda T; Thomas SM; Diaz FJ; Iwakuma T
    Oncogene; 2021 Aug; 40(31):5013-5025. PubMed ID: 34183772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.
    Yue X; Zhang C; Zhao Y; Liu J; Lin AW; Tan VM; Drake JM; Liu L; Boateng MN; Li J; Feng Z; Hu W
    Genes Dev; 2017 Aug; 31(16):1641-1654. PubMed ID: 28947497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The interplay between mutant p53 and the mevalonate pathway.
    Parrales A; Thoenen E; Iwakuma T
    Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
    Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
    Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
    Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
    Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8.
    Zhang Y; Huang X; Wang L; Cao C; Zhang H; Wei P; Ding H; Song Y; Chen Z; Qian J; Zhong S; Liu Z; Wang M; Zhang W; Jiang W; Zeng J; Yao G; Wen LP
    Biomaterials; 2021 Apr; 271():120720. PubMed ID: 33639563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
    Yang L; Song T; Cheng Q; Chen L; Chen J
    Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crizotinib Nanomicelles Synergize with Chemotherapy through Inducing Proteasomal Degradation of Mutp53 Proteins.
    Yi T; Qian J; Ye Y; Zhang H; Jin X; Wang M; Yang Z; Zhang W; Wen L; Zhang Y
    ACS Appl Mater Interfaces; 2023 Jan; 15(1):511-523. PubMed ID: 36578131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins.
    Mukherjee S; Maddalena M; Lü Y; Martinez S; Nataraj NB; Noronha A; Sinha S; Teng K; Cohen-Kaplan V; Ziv T; Arandkar S; Hassin O; Chatterjee R; Pirona AC; Shreberk-Shaked M; Gershoni A; Aylon Y; Elazar Z; Yarden Y; Schramek D; Oren M
    Proc Natl Acad Sci U S A; 2022 Apr; 119(17):e2119644119. PubMed ID: 35439056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy.
    He C; Li L; Guan X; Xiong L; Miao X
    Chemotherapy; 2017; 62(1):43-53. PubMed ID: 27322648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HMGA2 promotes intestinal tumorigenesis by facilitating MDM2-mediated ubiquitination and degradation of p53.
    Wang Y; Hu L; Wang J; Li X; Sahengbieke S; Wu J; Lai M
    J Pathol; 2018 Dec; 246(4):508-518. PubMed ID: 30175854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2.
    Wiech M; Olszewski MB; Tracz-Gaszewska Z; Wawrzynow B; Zylicz M; Zylicz A
    PLoS One; 2012; 7(12):e51426. PubMed ID: 23251530
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Pan M; Jiang C; Tse P; Achacoso N; Alexeeff S; Solorzano AV; Chung E; Hu W; Truong TG; Arora A; Sundaresan T; Suga JM; Thomas S; Habel LA
    J Clin Oncol; 2022 Jan; 40(2):171-179. PubMed ID: 34843402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.